Skip to content

REGN

Regeneron Pharmaceuticals, Inc.

Income statement

Income statement
Line, in USDLast 12 months202520242023202220212020201920182017201620152014201320122011201020092008
Revenue16.9B14.3B14.2B13.1B12.2B16.1B8.5B6.6B5.1B5.9B4.9B4.1B2.8B2.1B1.4B446M459M379M238M
Cost of revenue
———————403M238M203M195M242M129M118M84M4.2M2.1M1.7M923K
Gross profit———————6.15B4.91B5.67B4.67B3.86B2.69B1.99B1.29B0.44B0.46B0.38B0.24B
6.60B5.85B5.13B4.44B3.59B2.86B2.65B2.45B1.47B2.08B2.05B1.62B1.27B0.86B0.63B0.53B0.49B0.40B0.27B
2.76B2.70B2.95B2.63B2.12B1.82B1.35B1.34B1.13B1.32B1.18B0.84B0.52B0.35B0.21B0.12B65M53M49M
Other operating expenses
———————153M—195M105M151M76M37M—————
Operating income4.86B3.58B3.99B4.05B4.74B8.95B3.58B2.21B2.53B2.08B1.33B1.25B0.82B0.74B0.46B−0.21B−97M−74M−86M
Non-operating income
0.82B1.65B0.79B0.15B0.12B0.38B0.23B0.22B19M−1.1M−900K−27M−63M−47M−43M−18M−7.0M2.2M9.5M
Pretax income5.69B5.23B4.78B4.20B4.86B9.33B3.81B2.43B2.55B2.08B1.33B1.23B0.76B0.70B0.41B−0.22B−0.10B−72M−77M
Taxes
0.87B0.73B0.37B0.25B0.52B1.25B0.30B0.31B0.11B0.88B0.43B0.59B0.42B0.28B−0.34B−1.1M0−4.1M2.4M
Net income4.82B4.50B4.41B3.95B4.34B8.08B3.51B2.12B2.44B1.20B0.90B0.64B0.34B0.41B0.75B−0.22B−0.10B−68M−79M
Diluted EPS45.2941.4838.3434.7738.2271.9730.5218.4621.2910.347.705.522.983.726.75−2.45−1.26−0.85—
Diluted shares—108.6M115.1M113.7M113.5M112.2M115.1M114.6M114.8M115.9M116.3M115.2M113.4M111.3M115.4M90.6M82.9M——
Revenue growth—+1.0%+8.3%+7.8%−24.3%+89.1%+29.6%+27.4%−12.4%+20.8%+18.4%+45.5%+34.0%+52.7%+209.2%−2.9%+21.0%+59.1%—
Gross margin———————93.9%95.4%96.6%96.0%94.1%95.4%94.4%93.9%99.1%99.5%99.6%99.6%
Operating margin28.8%24.9%28.1%30.9%38.9%55.7%42.1%33.7%49.3%35.4%27.4%30.5%29.2%35.3%33.2%−46.0%−21.2%−19.5%−36.2%
Net margin28.5%31.4%31.1%30.1%35.6%50.2%41.3%32.3%47.5%20.4%18.4%15.5%12.0%19.7%54.4%−49.7%−22.8%−17.9%−33.2%